19th World Conference on Environmental Toxicology and Pharmacology
Tokyo, Japan
Mahmoud Said
Zagazig University, Egypt
Title: Ameliorative effect of Phoenix dactylifera on adverse effects of Linezolid in rats
Biography
Biography: Mahmoud Said
Abstract
Linezolid is one of the oxazolidinone anti-biotics that’s used to treat methicillin resistant staphylococcus aureus (MRSA) & vancomycin resistant staphylococcus aureus VRSA and was discovered in the 1990s and first approved for use in 2000. This study was aimed to investigate the adverse effects of linezolid on bone marrow, brain & kidney damaging effect of linezolid and counteracting these adverse effects using Phoenix dactylifera methanolic extract in rats. It was found that oral administration of linezolid (100 mg/kg body weight) given for 14 successive days induced a significant decrease in hemoglobin content (7.88±0.18 g/L) on the first day post-treatment, significant increase in serum urea (59.75±0.85) & serum creatinine (1.89±0.04) on the 14th day post- treatment and induced mild brain damage on the first day post treatment. The concurrent oral administration of Phoenix dactylifera methanolic extract (1000 mg/kg body weight) and linezolid (100 mg/kg body weight) for the same period corrected the damaging effects of linezolid of the hemoglobin content, urea, creatinine & brain condition of treated rats. It was concluded that methanolic extract of phoenix dactylifera clearly ameliorated these damaging effects of linezolid.